We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Real Estate 2.94%
3 Miscellaneous 0.82%
4 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
26
McKesson
MCK
$105B
$28.8M 0.94%
150,715
+24,767
+20% +$4.78M
AZN icon
27
AstraZeneca
AZN
$251B
$26.9M 0.87%
224,149
+51,982
+30% +$5.7M
CRSP icon
28
CRISPR Therapeutics
CRSP
$5.01B
$26.3M 0.85%
162,337
+11,379
+8% +$1.38M
HCA icon
29
HCA Healthcare
HCA
$91.8B
$25.8M 0.84%
124,743
-28,154
-18% -$5.74M
HUM icon
30
Humana
HUM
$47.6B
$25.7M 0.84%
58,135
+20,794
+56% +$9.08M
UTHR icon
31
United Therapeutics
UTHR
$21.5B
$25M 0.81%
139,438
+75,925
+120% +$14.5M
EXAS
32
DELISTED
Exact Sciences
EXAS
$24.8M 0.81%
199,654
+32,352
+19% +$3.86M
XRAY icon
33
Dentsply Sirona
XRAY
$1.96B
$24.2M 0.79%
382,344
+30,917
+9% +$2.04M
XLV icon
34
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
$23.8M 0.77%
188,930
+178,875
+1,779% +$21.9M
EW icon
35
Edwards Lifesciences
EW
$49.4B
$22.9M 0.75%
221,555
-17,200
-7% -$1.62M
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$31.9B
$22.8M 0.74%
134,495
-20,407
-13% -$2.99M
ARGX icon
37
argenx
ARGX
$61.3B
$22.4M 0.73%
74,410
+10,066
+16% +$2.86M
IDXX icon
38
Idexx Laboratories
IDXX
$40.2B
$22M 0.71%
34,814
– –
SYNH
39
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$21.8M 0.71%
243,633
-29,014
-11% -$2.45M
NBIX icon
40
Neurocrine Biosciences
NBIX
$15.2B
$20.7M 0.67%
212,891
– –
CRL icon
41
Charles River Laboratories
CRL
$13B
$20.2M 0.66%
54,674
+11,600
+27% +$3.87M
ASND icon
42
Ascendis Pharma A/S
ASND
$15.8B
$20.2M 0.66%
153,636
+35,300
+30% +$4.7M
GH icon
43
Guardant Health
GH
$23.6B
$19.7M 0.64%
158,727
– –
ISRG icon
44
Intuitive Surgical
ISRG
$133B
$19.6M 0.64%
63,888
– –
LH icon
45
Labcorp
LH
$26.3B
$19.4M 0.63%
81,915
-33,996
-29% -$7.75M
NVAX icon
46
Novavax
NVAX
$1.52B
$18.6M 0.6%
87,596
-17,580
-17% -$3.22M
PFE icon
47
Pfizer
PFE
$157B
$17.6M 0.57%
450,379
-254,880
-36% -$9.91M
WELL icon
48
Welltower
WELL
$168B
$16.9M 0.55%
203,083
– –
WAT icon
49
Waters Corp
WAT
$41B
$16.7M 0.54%
48,306
-54,404
-53% -$17.2M
MOH icon
50
Molina Healthcare
MOH
$10.8B
$16.1M 0.52%
63,610
+23,841
+60% +$5.99M
1
2
3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.